Biomarkers of type 2 inflammation as predictors of response to biologics for severe eosinophilic asthma.

Background: The relationship between pre-treatment levels of blood eosinophil count (BEC), fractional exhaled nitric oxide ( ) and sputum eosinophils (Sp-EOS) and treatment response to monoclonal antibodies (mAbs) in severe eosinophilic asthma (SEA) remains unclear. We evaluated pre-treatment levels of BEC, , Sp-EOS and their combinations as predictors of treatment responses in patients with SEA undergoing anti-interleukin (IL)-5/IL-5Rα or anti-IL-4Rα antibody therapies.

Methods: The study included 153 adult patients with SEA (59 anti-IL-5/IL-5Rα and 94 anti-IL-4Rα users).

Proteogenomic profiling predicts outcomes of adjuvant chemotherapy in extrahepatic cholangiocarcinoma.

Background & Aims: Cholangiocarcinoma is a heterogeneous disease, and its molecular characteristics and biomarkers and not yet fully understood. Here we performed comprehensive proteogenomic analyses to investigate the molecular landscape of extrahepatic cholangiocarcinoma (EH-CCA).

Methods: To identify potential biomarkers, prespecified exploratory analyses were conducted within the STAMP trial-a randomized phase 2 trial of adjuvant capecitabine or gemcitabine plus cisplatin (GemCis) for patients with resected EH-CCA.

Serum neuropilin-1 level may predict airway remodeling based on age and smoking status in asthma.

Background: Airway remodeling in asthma is induced by the production of vascular endothelial growth factor, and this process is mediated by neuropilin-1 (NRP-1).

Objective: To investigate the association between the serum level of NRP-1 and clinical characteristics in asthma.

Methods: We measured the serum level of NRP-1 and performed subgroup analysis of NRP-1 according to the clinical characteristics of 421 asthma patients registered in the Cohort for Reality and Evolution of Adult Asthma in Korea.

Predictors of asthma exacerbation between high and low blood eosinophil counts.

Background: Despite treatment advances, managing asthma remains challenging owing to variability in response across different type 2 inflammation phenotypes. We aimed to compare the differences in pre-treatment profiles related to 12-month asthma exacerbation in patients with baseline high and low blood eosinophil count (BEC) levels.

Methods: This study included 438 and 231 patients with asthma with pre-treatment BEC levels >300 cells·μL (high BEC) and <150 cells·μL (low BEC), respectively, and no history of systemic corticosteroid use.

Real-World Effectiveness and Safety of Mepolizumab in Severe Eosinophilic Asthma: Insights From the Korean Severe Asthma Registry (KoSAR).

Mepolizumab, an interleukin-5 antagonist, is globally recognized for its efficacy in randomized controlled trials for the treatment of severe eosinophilic asthma. The present study explored its real-world effectiveness and safety in a Korean cohort, filling a critical gap in current research. This multi-center retrospective study used data from the Korean Severe Asthma Registry, involving 67 patients treated with mepolizumab for uncontrolled severe asthma between September 2017 and July 2022.

Comorbidities associated with adult asthma according to severity: analysis of data from the National Health Insurance Sharing Service.

Background: Asthma is a heterogenous disease having varied phenotypes. The comorbidities associated with asthma vary with age and disease severity. The well-known asthma related comorbid conditions include rhinitis, gastroesophageal reflux disease (GERD), hypertension, obstructive sleep apnea, hormonal disorders, and psychiatric disorders.

Concurrent Blood Eosinophils and FeNO as Biological Therapy Indicators in Severe Asthma: Findings From the Precision Medicine Intervention in Severe Asthma Study.

Background: The combination of pretreatment peripheral blood eosinophil count (BEC) and FeNO levels for optimizing the therapeutic response of T2-biologics in patients with severe eosinophilic asthma (SEA) remains unclear.

Objective: To compare longitudinal clinical outcome changes across subgroups stratified by the combination of high and low levels of BEC and FeNO.

Methods: Overall, 278 patients with SEA (anti-IL-5/IL-5Rα users: n = 82; and anti-IL-4Rα users: n = 196) were stratified based on pretreatment BEC and FeNO levels and observed for 6 to 12 months.

Relationships Between Chronic Cough and Asthma Control and Quality of Life in Patients With Severe Asthma: A 6-Month Longitudinal Analysis.

Background: The prevalence and clinical implications of chronic cough (CC) in patients with severe asthma receiving asthma treatment remain relatively unknown.

Objective: This study aimed to evaluate the relationships between CC and asthma control and quality of life (QoL) in patients with severe asthma through longitudinal analysis.

Methods: Baseline and 6-month follow-up data from the Korean Severe Asthma Registry were analyzed.

Longitudinal multi-trajectory phenotypes of severe eosinophilic asthma on type 2 biologics treatment.

Background: Limited understanding exists regarding the progression trajectory of severe eosinophilic asthma (SEA) patients on type 2 biologics therapies.

Objective: We aim to explore distinct longitudinal phenotypes of these patients based on crucial asthma biomarkers.

Methods: We enrolled 101 adult patients with SEA.

Progranulin derivative attenuates lung neutrophilic infiltration from diesel exhaust particle exposure.

Background: Air pollutants, such as diesel exhaust particles (DEPs), induce respiratory disease exacerbation with neutrophilic infiltration. Progranulin (PGRN), an epithelial cell and macrophage-derived secretory protein, is associated with neutrophilic inflammation. PGRN is digested into various derivatives at inflammatory sites and is involved in several inflammatory processes.

Long-term Safety and Efficacy of Dupilumab in Patients With Uncontrolled, Moderate-to-Severe Asthma Recruited From Korean Centers: A Subgroup Analysis of the Phase 3 LIBERTY ASTHMA TRAVERSE Trial.

Purpose: Long-term data are limited on the safety and efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma from Korea. The current subgroup analysis was designed to evaluate the long-term safety and efficacy of dupilumab in patients enrolled from Korean centers in the parent studies (phase 2b and QUEST) and who participated in the TRAVERSE open-label extension (OLE) study.

Methods: TRAVERSE was a global, multicenter, OLE study that assessed the safety and efficacy of dupilumab 300 mg every 2 weeks for up to 96 weeks in patients (n = 2,282) with uncontrolled, moderate-to-severe asthma who completed prior dupilumab asthma clinical trials.

Transcriptomic Expression of T2-Inflammation Genes in Peripheral Blood Mononuclear Cells and Longitudinal Clinical Outcomes in Asthma: Insights from the COREA Study.

Background: Gene expression can provide distinct information compared to clinical biomarkers in the context of longitudinal clinical outcomes in asthma patients.

Objective: This study examined the association between the gene expression levels of upstream (IL-25, IL-33, and TSLP) and downstream cytokines (IL-5, IL-4, and IL-13) in the T2 inflammatory pathway with a 12-month follow-up of exacerbation, lung function, and steroid use.

Methods: Transcriptomic sequencing analysis was performed on peripheral blood mononuclear cells from 279 adult asthmatics.

Characteristics of Severe Asthma in the Elderly: Observations From the Korean Severe Asthma Registry (KoSAR).

Purpose: Few studies have compared the clinical characteristics of severe asthma (SA) in elderly patients compared to that in nonelderly patients.

Methods: We analyzed data from the Korean SA Registry, a nationwide, real-world observational study of SA in Korea. The baseline clinical characteristics, disease control status, and medication use of the patients were compared between elderly (≥ 65 years) and nonelderly groups.

Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR.

Purpose: Severe asthma is associated with high morbidity and healthcare utilization; however, treatment options for these patients are limited. This study aimed to determine the therapeutic effects of biologics in clinical practice.

Methods: This multicenter, retrospective cohort study included 136 patients who received biologics for at least 4 months between September 2017 and July 2022 at 25 medical centers affiliated with the Korean Severe Asthma Registry (KoSAR).

Association of Cough Severity with Asthma Control and Quality of Life in Patients with Severe Asthma.

Purpose: Symptoms are important components in determining asthma control and in the adjustment of treatment levels. However, clinical relevance of cough in severe asthma is not well-understood. This study aimed to evaluate the severity and association of cough with patient-reported outcomes (PROs) in patients with severe asthma.

Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgE-Fc protein in subjects with Atopy: Results from the First-in-Human study.

Background: YH35324, a long-acting IgETrap-Fc fusion protein, is a novel therapeutic agent for immunoglobulin E (IgE)-mediated allergic diseases. This randomized, double-blind, placebo/active-controlled, single ascending dose Phase 1 study assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YH35324 in subjects with atopy.

Methods: Eligible subjects were healthy subjects or atopic adults with mild allergic rhinitis, atopic dermatitis, food allergy, or urticaria, and a serum total IgE level of 30-700 IU/mL (Part A) or > 700 IU/mL (Part B).

PIBF1 regulates trophoblast syncytialization and promotes cardiovascular development.

Proper placental development in early pregnancy ensures a positive outcome later on. The developmental relationship between the placenta and embryonic organs, such as the heart, is crucial for a normal pregnancy. However, the mechanism through which the placenta influences the development of embryonic organs remains unclear.

Blood transcriptome differentiates clinical clusters for asthma.

Background: In previous studies, several asthma phenotypes were identified using clinical and demographic parameters. Transcriptional phenotypes were mainly identified using sputum and bronchial cells.

Objective: We aimed to investigate asthma phenotypes via clustering analysis using clinical variables and compare the transcription levels among clusters using gene expression profiling of the blood.

Predictors of Early and Late Lung Function Improvement in Severe Eosinophilic Asthma on Type2-Biologics in the PRISM Study.

Background: The determinants linked to the short- and long-term improvement in lung function in patients with severe eosinophilic asthma (SEA) on biological treatment (BioT) remain elusive.

Objective: We sought to identify the predictors of early and late lung function improvement in patients with SEA after BioT.

Methods: 140 adult patients with SEA who received mepolizumab, dupilumab, or reslizumab were followed up for 6 months to evaluate improvement in forced expiratory volume in one second (FEV).

Effects of bepotastine, a nonsedating H1-antihistamine, for the treatment of persistent cough and allergic rhinitis: a randomised, double-blind, placebo-controlled trial.

Background: Empirical therapy with oral histamine-1 receptor antagonists (H1RAs) is often used for patients with suspected upper airway cough syndrome. No placebo-controlled trials with nonsedating H1RAs (nsH1RAs) have evaluated validated cough outcomes. The objective of the present study was to assess the effect of an nsH1RA, bepotastine, on cough outcomes in patients with allergic rhinitis and persistent cough.